Overview

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study to access the safety and tolerability of KX2-391 ointment in subjects who have Actinic Keratosis. This study will also access the amount of KX2-391 drug that enters the blood stream through dermal application of the ointment.
Phase:
Phase 1
Details
Lead Sponsor:
Athenex, Inc.
Kinex Pharmaceuticals Inc
Treatments:
Tirbanibulin